TearCare System for Meibomian Gland Dysfunction: Interview with Reay H. Brown, CMO of Sight Sciences

Sight Sciences, a medtech company based in California, specializes in devices to treat glaucoma and dry eye disease. The company has recently announced FDA 510(k) clearance for the TearCare System, a device designed to treat meibomian gland dysfuncti...

Source: Medgadget - January 27, 2022 Category: Medical Devices Authors: Conn Hastings Tags: Exclusive Ophthalmology Source Type: blogs